Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37068504

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2023 May 20
First author
Shitara K

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 May 20;401(10389):1630-1631. doi: 10.1016/S0140-6736(23)00732-8.
    note
    Source null
    related pmid
    37068506
    relationship
    Comment in
  2. citation
    Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):344. doi: 10.1038/s41575-023-00785-0.
    note
    Source null
    related pmid
    37085616
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2023 Jun;20(6):354. doi: 10.1038/s41571-023-00773-y.
    note
    Source null
    related pmid
    37138050
    relationship
    Comment in
  4. citation
    Lancet. 2023 Jul 22;402(10398):290. doi: 10.1016/S0140-6736(23)01481-2.
    note
    Source null
    related pmid
    37481269
    relationship
    Erratum in
  5. citation
    Lancet. 2024 Jan 6;403(10421):30. doi: 10.1016/S0140-6736(23)02762-9.
    note
    Source null
    related pmid
    38101428
    relationship
    Erratum in

Authors and identifiers

  1. name
    Shitara K
    type
    Author
  2. name
    Lordick F
    type
    Author
  3. name
    Bang YJ
    type
    Author
  4. name
    Enzinger P
    type
    Author
  5. name
    Ilson D
    type
    Author
  6. name
    Shah MA
    type
    Author
  7. name
    Van Cutsem E
    type
    Author
  8. name
    Xu RH
    type
    Author
  9. name
    Aprile G
    type
    Author
  10. name
    Xu J
    type
    Author
  11. name
    Chao J
    type
    Author
  12. name
    Pazo-Cid R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Shitara K
    type
    Author
  2. name
    Lordick F
    type
    Author
  3. name
    Bang YJ
    type
    Author
  4. name
    Enzinger P
    type
    Author
  5. name
    Ilson D
    type
    Author
  6. name
    Shah MA
    type
    Author
  7. name
    Van Cutsem E
    type
    Author
  8. name
    Xu RH
    type
    Author
  9. name
    Aprile G
    type
    Author
  10. name
    Xu J
    type
    Author
  11. name
    Chao J
    type
    Author
  12. name
    Pazo-Cid R
    type
    Author
bibliography ids
  1. nci-bib-9458027632463aad56879b1e
book metadata
content sha256
ffdc12e21e3f01ee07fc966c0896f583bf1f1d53d43624c3c2a2b73b41f22ab1
document type
citation
dois
  1. 10.1016/S0140-6736(23)00620-7
electronic publication date
display
2023 Apr 15
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37068504
immutable id
pubmed:37068504@ffdc12e21e3f01ee07fc966c0896f583bf1f1d53d43624c3c2a2b73b41f22ab1
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10389
name
Lancet (London, England)
nlm unique id
2985213R
pages
1655-1668
volume
401
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 May 20;401(10389):1630-1631. doi: 10.1016/S0140-6736(23)00732-8.
    note
    Source null
    related pmid
    37068506
    relationship
    Comment in
  2. citation
    Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):344. doi: 10.1038/s41575-023-00785-0.
    note
    Source null
    related pmid
    37085616
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2023 Jun;20(6):354. doi: 10.1038/s41571-023-00773-y.
    note
    Source null
    related pmid
    37138050
    relationship
    Comment in
  4. citation
    Lancet. 2023 Jul 22;402(10398):290. doi: 10.1016/S0140-6736(23)01481-2.
    note
    Source null
    related pmid
    37481269
    relationship
    Erratum in
  5. citation
    Lancet. 2024 Jan 6;403(10421):30. doi: 10.1016/S0140-6736(23)02762-9.
    note
    Source null
    related pmid
    38101428
    relationship
    Erratum in
outcomes validated
false
pmid
37068504
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
ef6b1b98c869015aad29bdfa603f8538408a6f71d0a4f631fced8be2e2de8e03
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 May 20
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Multicenter Study
  3. Clinical Trial, Phase III
  4. Journal Article
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37068504/
title
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.

Preserved source evidence · Not medical advice